Oxford BioDynamics plc (LSE: OBD)

https://www.oxfordbiodynamics.com

LinkedIn: https://linkedin.com/company/oxford-biodynamics

Oxford BioDynamics Plc (AIM: OBD) ("Oxford BioDynamics") is a biotechnology company focused on the discovery and development of 3D genomic biomarkers for use within the pharmaceutical and biotechnology industry. The Company's award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine. In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re-positioning programs, enabling the personalization of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical. In April 2019, Oxford BioDynamics received the Queen's Award for Enterprise: Innovation. The Queen's Awards for Enterprise are the most prestigious awards for UK businesses. The Company is headquartered in the UK and listed on the London Stock Exchange's AIM under the ticker "OBD". *

	Start	2007-04-01 established
	Group	Oxford BioDynamics (Group)
	Predecessor	Oxford BioDynamics Ltd. (OBD)
	Industry	biomarker discovery technology
	Industry 2	epigenetics / epigenomics
	Person	Burrows, Jon (Oxford BioDynamics 202011 CEO formerly Expression Pathology + Ventana + Novartis + Chiron)

	Region	Oxford, Oxfordshire
	Country	United Kingdom (GB)
	Street	Alec Issigonis Way Oxford Business Park North, The Quorum, First Floor, Building 7600 C
	City	OX4 2JZ Oxford, Oxfordshire
	Tel	+44-1865-518910
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Oxford BioDynamics plc. (11/2/20). "Press Release: Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch Disease Severity Program for COVID-19". Oxford.

		Record changed: 2023-07-10

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Oxford BioDynamics (Group)

[1] Oxford BioDynamics plc. (11/2/20). "Press Release: Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance EpiSwitch Disease Severity Program for COVID-19". Oxford....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)